louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02599116: Gastrointestinal Microbiome Study of Appendiceal Cancer
Official title: A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pseudomyxoma Peritonei
Appendiceal Neoplasm
Cancer, Appendiceal
Keywords: cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
microbiome
Lead sponsor: Mercy Medical Center
Sponsor class: OTHER
Collaborators: name: University of California, San Diego
First posted: 2015-11-06
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study analyzes the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Participants will provide fecal samples pre- and post-operatively.

Detailed description: Analysis of the human microbiome is an attempt to define how changes in the human microbiome are associated with health or disease.

Eligible participants scheduled to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal cancer will provide fecal samples pre- and post-operatively. Investigators will analyze potential changes in the gastrointestinal microbiome and make comparisons to an age-matched healthy sample.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of appendiceal cancer with peritoneal spread
* Candidate for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
* ≥18 and ≤ 80 years of age
* Eastern Cooperative Oncology Group performance status score of ≤2/Karnofsky performance status (KPS) ≥70%
* Signed Institutional Review Board approved informed consent

Exclusion Criteria:

* \<18 years of age
* Pregnant women
* Concurrent severe medical problems unrelated to malignancy

Primary outcomes:
measure: Determine whether the intestinal microbiome of patients with appendiceal tumors with peritoneal carcinomatosis differs from that of a healthy, age-matched cohort
timeFrame: 36 months
Secondary outcomes:
measure: Compare the gut microbiome of appendiceal tumors by histopathology
timeFrame: 36 months
Other outcomes:
measure: Identify potential biomarkers associated with appendiceal tumors
timeFrame: 36 months
measure: Identify alterations in the gut microbiome post-CRS/HIPEC
timeFrame: 36 months
Locations:
city: Baltimore
country: United States
facility: Mercy Medical Center
state: Maryland
Study officials:
affiliation: Mercy Medical Center
name: Armando Sardi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gilbreath JJ, Semino-Mora C, Friedline CJ, Liu H, Bodi KL, McAvoy TJ, Francis J, Nieroda C, Sardi A, Dubois A, Lazinski DW, Camilli A, Testerman TL, Merrell DS. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis. 2013 Jul 12;8:105. doi: 10.1186/1750-1172-8-105.
Clinical trial NCT06893016: Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Obesity
Lead sponsor: Guangdong Raynovent Biotech Co., Ltd
Sponsor class: INDUSTRY
First posted: 2025-03-25
Enrollment: 640
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years.
2. Body mass index ≥ 28 kg/m2 or ≥24kg/m² to \<28 kg/m2 with at least 1 of the following weight-related comorbidities: a) Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or the use of at least one antihypertensive medication to maintain normal blood pressure;b) Fasting triglycerides (TG) ≥1.70 mmol/L, fasting low-density lipoprotein cholesterol (LDL-C) ≥4.1 mmol/L, fasting high-density lipoprotein cholesterol (HDL-C) \<1.04 mmol/L, or the need for at least one lipid-lowering treatment to maintain normal lipid levels; c) Obstructive sleep apnea syndrome; d) Fatty liver; e) Cardiovascular disease; e) Polycystic ovary syndrome.
3. History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.

Exclusion Criteria:

1. Obesity known to be caused by monogenic mutations, other diseases, or medications.
2. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2.
3. A history of moderate to severe depression at any time in the past or a score of ≥15 on the PHQ-9 questionnaire at screening; a history of bipolar disorder, schizophrenia, or other severe psychiatric disorders.
4. A history of organ transplantation (excluding corneal transplant), or being currently prepared to undergo organ transplantation.
5. Plans to quit smoking during the study period
6. Allergic constitution (allergic to multiple medications or foods), or those known to be allergic to RAY1225, GLP-1 receptor agonists, or GLP-1 related drugs.

Primary outcomes:
measure: Percent Change From Baseline in Body Weight at Week 52
timeFrame: Baseline and Week 52
measure: Number of Participants who Achieved a ≥ 5% Reduction in Body Weight from Baseline at Week 52
timeFrame: Baseline and Week 52
Secondary outcomes:
measure: Change From Baseline in Waist Circumference at Week 52
timeFrame: Baseline and Week 52
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
Study officials:
References:
Clinical trial NCT02912416: Efficacy of Probiotics on Iron Status During Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prevention of Iron Deficiency
Lead sponsor: Probi AB
Sponsor class: INDUSTRY
First posted: 2016-09-23
Enrollment: 326
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Determine the effect of probiotics on improving iron status in a population of healthy, pregnant women.


Eligibility criteria: Inclusion Criteria:

* Healthy, pregnant women, aged 18-42 years, with a singleton gestation
* Inclusion at 10-12 weeks of gestation
* BMI ≥ 18 and ≤ 30 at baseline
* Provide signed and dated informed consent form
* Willing to comply with all study procedures

Exclusion Criteria:

* Serum ferritin level \<20 µg/L or Hb\<110 g/L at baseline (visit 1)
* Chronic diseases associated with anemia
* Known Thalassemia
* Hyperemesis gravidarum
* Chronic gastrointestinal disease (inflammable bowel diseases; Crohn's disease, Ulcerative Colitis; diarrheal disease)
* Known gluten intolerance, lactose intolerance, milk protein allergy
* Taking antibiotics within four weeks before inclusion
* Blood or plasma donation within three (3) months prior to baseline
* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
* Smoking or use of nicotine-containing products (currently or during the last three \[3\] months)
* History of alcohol abuse, or excessive intake of alcohol, as judged by the Investigator
* Hypersensitivity to any of the ingredients in the study products
* Any other reason for exclusion, as judged by the Investigator

Primary outcomes:
measure: Serum ferritin level
timeFrame: Week 28 of gestation
Secondary outcomes:
Other outcomes:
Locations:
city: Malmö
country: Sweden
facility: CuraÖresund
Study officials:
References:
Clinical trial NCT03553316: Drug-Drug Interaction Between PK101-001 and PK101-002
Official title: A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Arthritis
Lead sponsor: PMG Pharm Co., Ltd
Sponsor class: INDUSTRY
First posted: 2018-06-12
Enrollment: 49
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy adults ≥ 19 years of age (on the day of screening)
* No congenital or chronic diseases and no abnormal signs determined by medical examinations
* Not abnormal or not clinical significant lab values
* 90mmHg ≤ (SBP) ≤ 139mmHg, 60mmHg ≤ (DBP) ≤ 89mmHg
* 18Kg/(m)\^2 ≤ (BMI) ≤30Kg/(m)\^2

Exclusion Criteria:

* Subjects who were administered below medications within 30 days (barbiturates, drugs of induced or suppressive drug metabolizing enzyme, etc)
* Subjects who were administered medications of prohibition within 10 days
* Heavy drinking within 30 days (female: over 14units/week, male:over 21units/week)
* Heavy smoker within 30 days (over 20 cigarettes per day)
* Subjects who previously participated in other clinical trials or bioequivalence Test within 90 days
* Subjects who donated whole blood within 60 days or donated component blood within 14 days or received blood transfusion within 30 days
* Subjects who have hypersensitivity for investigational products

Primary outcomes:
measure: AUCτ
timeFrame: 0, 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour
measure: Cmax,ss
timeFrame: 0, 0.5, 1, 1.5, 2, 2.33, 2.67, 3, 3.5, 4, 6, 8, 12, 24, 36, 48 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: H Plus Yangji Clinical Research Center
Study officials:
affiliation: H Plus Yangji Clinical Research Center
name: Seung-Hyun Kang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00824616: A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
Official title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-01-19
Enrollment: 68
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.


Eligibility criteria: Inclusion Criteria:

* Participant has Type 2 Diabetes Mellitus

Exclusion Criteria:

* Participant has a history of Type 1 Diabetes Mellitus or ketoacidosis
* Participant is on a weight loss program and is not in the maintenance phase or is taking a weight loss medication
* Participant has had surgery within 30 days of starting the study or has planned major surgery

Primary outcomes:
measure: Change From Baseline in Hemoglobin A1c (HbA1c) Level
timeFrame: Baseline (Day 1) and End of Treatment (Week 20)
measure: Number of Participants Who Experienced One or More Episodes of Hypoglycemia (Symptomatic or Asymptomatic)
timeFrame: From first dose of study drug (Week 0) to last dose of study drug (Week 20)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04663516: Effectiveness of Exercise Through Video Games in Reducing Fatigue Among Children With Leukemia
Official title: Effectiveness of Exergaming in Reducing Fatigue Among Children With Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fatigue
Childhood ALL
Keywords: Exergaming
fatigue
Leukemia
Children
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2020-12-11
Enrollment: 46
Sex: ALL
Minimum age (years): 6
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: 40 children with cancer who fulfills the inclusion criteria will be included. Participants will be recruited from King Fahad Children's Cancer Center, King Fahad Medical City and King Khaled University Hospital. After obtaining written formal consent, children will be randomly assigned to two groups, control and experimental. Experimental group will play 60 minutes of Wii physical activity games for three weeks, twice each week. while control group will receive conventional therapy. Fatigue will be assessed using pediatric multidimensional fatigue scale- child proxy before, weekly during the study and after. Functional capacity will be measured by six minute walk test before and after study duration, and physical activity will be repeatedly measured by godin-shephard leisure time physical activity questionnaire. All data will be analyzed using appropriate statistical analysis.

Detailed description: The intervention group:

The investigator will:

* handle accompanying each child to the play room, turn on the Wii and ask the child to choose the game he/she prefers to play from the games provided by wii console that requires the movement of the whole body: upper, lower and trunk.
* Monitor the child while playing, helping with the instructions of the game if the child needs assistance as it is only provided in English from the console.
* heart rate and oxygen saturation are planned to be measured every 15 minutes.

The duration is designed to be 60 minutes per session, but the child is allowed to rest for the time needed during the session if he/she feels tired. or if the oxygen saturation of the child reaches 93. or the heart rate reaches the predicted maximum heart rate.

Eligibility criteria: Inclusion Criteria:

* diagnosed with leukemia, receiving chemotherapy, or off therapy within 6 months.

Exclusion Criteria:

* bone / pulmonary metastasis, having physical or cognitive disability preventing the child from being able to use the controller and board of the console.

Primary outcomes:
measure: pediatric quality of life multidimensional fatigue scale
timeFrame: one month
measure: six minute walk test
timeFrame: one month
Secondary outcomes:
measure: the Godin shepherd leisure time physical activity questionnaire
timeFrame: one week
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: King Fahad Medical City
Study officials:
affiliation: MSc student
name: afnan masoud
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02003716: DeFRA Questionnaire as an Anamnestic Form
Official title: Use of the DeFRA Questionnaire as a "Primary Anamnestic Form" Through a Large Scale Screening of the Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoporosis
Lead sponsor: Valmontone Hospital
Sponsor class: OTHER
First posted: 2013-12-06
Enrollment: 767
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: general population, never screened before for osteoporosis and never subject to treatment

Brief summary: The DeFRA questionnaire is a new validated algorithm derived from FRAX. Here we use the DeFRA as a "primary anamnestic from" to identify subjects at risk of osteoporosis in a population never screened before and never treated for this disease.

Detailed description: There is an increasing recognition that the management of osteoporosis requires the characterization of fracture risk to be based on absolute risk rather than single measures such as bone mineral density (BMD). However, the threshold for pharmacological intervention for osteoporosis remains controversial.

The aim of the present project is to perform a large scale study to identify subjects at risk of osteoporosis by administering the DeFRA questionnaire in a population never screened or treated before for osteoporosis.

DeFRA questionnaire will be administered before and after DEXA scanning, to further validate the questionnaire and to highlight the predictive value of this protocol as a tool to screen the general population.

Eligibility criteria: Inclusion Criteria:

* age: 50 to 70 years
* no overt pathologies
* never screened before for osteoporosis
* no prior use of drugs for osteoporosis
* signed informed consent form

Exclusion Criteria:

* overt pathologies (cancer, neurodegenerative diseases, renal or hepatic insufficiency)
* use of the following drugs: cortisones, loop diuretics, antiepileptic drugs, aromatase inhibitors, dicoumarols, thyroxin in suppressive therapy, antiosteoporosis drugs)
* patients who underwent radiation therapy
* hypercalcemia or alterations of the phospho-calcic metabolism
* patients with metabolic diseases of the bone (including hyperparathyroidism or Paget disease)

Primary outcomes:
measure: percent risk of a fracture
timeFrame: day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Valmontone
country: Italy
facility: Valmontone Hospital
state: Roma
Study officials:
affiliation: Valmontone Hospital
name: Vincenzo Dell'Anna, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05036616: Separation Versus Integrated Approach in Combining ECMO With CRRT
Official title: Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: AKI
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2021-09-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients have to be admitted to the ICU

Brief summary: This investigation aims to evaluate the filter life time of CRRT membrane and complication of combining ECMO and CRRT.


Eligibility criteria: Inclusion Criteria:

1. \> 18 years
2. Refractory acidosis (pH\<7.2 or HCO3\<15)
3. Refractory volume overload
4. Refractory hyperkalemia (K\>6.2mEq/L or EKG change)
5. Anuria or oliguria (urine output \<0.5 mL/kg/hr for 6-12hr)
6. High BUN \>100 mg/dL or uremic symptom
7. Increase intracranial pressure

Exclusion Criteria:

1. Pregnancy
2. Not use heparin in ECMO
3. Chronic kidney disease with CRRT
4. AKI with Glomerulonephritis, Interstitial nephritis, Vassculitis or Urinary tract obstruction

Primary outcomes:
measure: Circuit lifetime
timeFrame: 72 hours
Secondary outcomes:
measure: Cost-Effectiveness
timeFrame: 72 hours
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Sasipha tachaboon
Study officials:
References:
Clinical trial NCT06109116: Effects of Self-myofascial Release on Hamstring Flexibility in Patients With Non Specific Low Back Pain
Official title: Effects of Self-myofascial Release on Hamstring Flexibility in Patients With Non Specific Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nonspecific Low Back Pain
Keywords: Hamstring flexibility
Non specific low back pain
Self myofascial release
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-10-31
Enrollment: 24
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this preliminary study suggest the addition of self myofascial release to a therapeutic exercise program in reducing hamstring flexibility and would have additional effects on decreasing pain intensity in individuals with non specific low back pain.

Detailed description: There are different treatments that can affect the facial tissue, but MFR techniques have shown promising effects in reducing pain, improving flexibility and daily activities, these techniques involve specifically guided load long-duration mechanical forces to manipulate the myofascial complex (16). Fascia is part of a body-wide tensional force "transmission system" as facial system is innervated by mechano receptors, that when manual pressure is applied may create a range of response via myofascial pathway by transmitting tensional force and decreasing muscle tension that facilitate movement and reduce pain, However in reviewing the literature, there is still theory and hypothesis in relation to the exact mechanism underlying the efficacy of facial manual therapy Self myofascial release (SMR) works under the same principle as myofascial release technique in which individual use their own body mass to exert pressure on soft tissues by tennis ball to the plantar surface of the foot and is widely used to increase flexibility and range of movement further along the posterior muscles of a proposed anatomy train.

Eligibility criteria: Inclusion Criteria:

* Patients with nonspecific low back pain for at least 3 months.
* \>20 degree active knee extension loss with hip in 90 degree of flexion
* NPRS \>3
* Patients willing to participate and take treatment.

Exclusion Criteria:

* Patients having severe orthopedic, neurological disease
* Patients having specific diagnose cause of low back pain (infection, tumor, lumbar spine fracture, radicular pain, cauda equina syndrome)
* Involvement in regular flexibility yoga program
* Recent(\<6 months) lower limb, spinal or soft tissue injuries
* Any integumentary contraindication to MFR

Primary outcomes:
measure: Active knee extension test
timeFrame: 3 weeks
measure: Numeric pain rating scale
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Riphah Internatinal Hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Asghar Khan, DPT,DSc PT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01986816: Return on Investment on Lap Gastric Bypass Regarding Quality of Life
Official title: Lap Gastric Bypass and Its Impact on Wheightloss, QoL and Economic Cost
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Obesity
Keywords: Obesity
Bariatric surgery
Laparoscopic gastric bypass
Quality of life
QALY
Lead sponsor: Lund University
Sponsor class: OTHER
Collaborators: name: Landstinget i Kalmar Län
First posted: 2013-11-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Populutaion af morbid obese patients with BMI of 35 or more eligible for bariatric surgery

Brief summary: The purpose of this study is to investigate the cost of treatment and adverse efffects therof corresponds to quality of life improvements and expected wheightloss.


Eligibility criteria: Inclusion Criteria:

* BMI \> 35
* age 18-60 years

Exclusion Criteria:

* Prior bariatric surgery
* Prior gastric surgery

Primary outcomes:
measure: Significant wheigtloss
timeFrame: 1 year
Secondary outcomes:
measure: Quality of life improvement
timeFrame: 3 months and 12 months post surgery
Other outcomes:
Locations:
city: Kalmar
country: Sweden
facility: Kalmar County Hospital
state: Kalmar Län
Study officials:
References: